Metformin, a common clinical drug used to treat
diabetes mellitus, is found with potential antiobese actions as reported in increasing evidences. However, the detailed mechanisms of
metformin-antiobesity-related
hypertension remain unrevealed. We have utilized the bioinformatics strategy, including network pharmacology and molecular docking analyses, to uncover pharmacological targets and molecular pathways of bioactive compounds against clinical disorders, such as
cancers,
coronavirus disease 2019. In this report, the in-silico approaches using network pharmacology and molecular docking was utilized to identify the core targets, pharmacological functions and mechanisms of
metformin against
obesity-related
hypertension. The networking analysis identified 154 differentially expressed genes of
obesity and
hypertension, and 21 interaction genes, 6 core genes of
metformin treating
obesity-related
hypertension. As results, molecular docking findings indicated the binding capability of
metformin with key
proteins, including
interleukin 6 (IL-6) and
chemokine (C-C motif) Ligand 2 (CCL2) expressed in
obesity- and
hypertension-dependent tissues.
Metformin-exerted antihypertension/
obesity actions involved in metabolic regulation, inflammatory suppression. And antihypertension/
obesity mechanisms of
metformin were revealed, including regulation of inflammatory and immunological signaling pathways for ameliorating microenvironmental homeostasis in targeting tissues. In conclusion, our current bioinformatics findings have uncovered all pharmacological targets, biological functions and signaling pathways of
metformin treating
obesity-related
hypertension, thus promoting its clinical application in future.